Literature DB >> 27288544

Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.

Dario R Roque1, Liza Makowski2, Ting-Huei Chen3, Naim Rashid4, D Neil Hayes5, Victoria Bae-Jump6.   

Abstract

OBJECTIVE: The Cancer Genome Atlas (TCGA) identified four integrated clusters for endometrial cancer (EC): POLE, MSI, CNL and CNH. We evaluated differences in gene expression profiles of obese and non-obese women with EC and examined the association of body mass index (BMI) within the clusters identified in TCGA.
METHODS: TCGA RNAseq data was used to identify genes related to increasing BMI among ECs. The POLE, MSI and CNL clusters were composed mostly of endometrioid EC. Patient BMI was compared between these three clusters with one-way ANOVA. Association between gene expression and BMI was also assessed while adjusting for confounding effects of potential confounding factors. p-Values testing the association between gene expression and BMI were adjusted for multiple hypothesis testing over the 20,531 genes considered.
RESULTS: Mean BMI was statistically different between the ECs in the CNL (35.8) versus POLE (29.8) cluster (p=0.006) and approached significance for the MSI (33.0) versus CNL (35.8) cluster (p=0.05). 181 genes were significantly up- or down-regulated with increasing BMI in endometrioid EC (q-value<0.01), including LPL, IRS-1, IGFBP4, IGFBP7 and the progesterone receptor. DAVID functional annotation analysis revealed significant enrichment in "cell cycle" (adjusted p-value=1.5E-5) and "DNA metabolic processes" (adjusted p-value=1E-3) for the identified genes.
CONCLUSIONS: Obesity related genes were found to be upregulated with increasing BMI among endometrioid ECs. Patients with POLE tumors have the lowest median BMI when compared to MSI and CNL. Given the heterogeneity among endometrioid EC, consideration should be given to abandoning the Type I and II classification of EC tumors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27288544      PMCID: PMC4961559          DOI: 10.1016/j.ygyno.2016.06.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25).

Authors:  Abel López-Bermejo; Javad Khosravi; José Manuel Fernández-Real; Vivian Hwa; Katherine L Pratt; Roser Casamitjana; Maria M Garcia-Gil; Ron G Rosenfeld; Wifredo Ricart
Journal:  Diabetes       Date:  2006-08       Impact factor: 9.461

2.  Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis.

Authors:  Gilbert P Pellerin; Michael A Finan
Journal:  Am J Obstet Gynecol       Date:  2005-11       Impact factor: 8.661

3.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

4.  Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium.

Authors:  Adrienne S McCampbell; Russell R Broaddus; David S Loose; Peter J A Davies
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

5.  Overexpression of insulin receptor substrate-1, but not insulin receptor substrate-2, protects a T cell hybridoma from activation-induced cell death.

Authors:  Li Li; Xiulan Qi; Mark Williams; Yufang Shi; Achsah D Keegan
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

6.  Increased expression of insulin receptor substrate-1 in human pancreatic cancer.

Authors:  U Bergmann; H Funatomi; M Kornmann; H G Beger; M Korc
Journal:  Biochem Biophys Res Commun       Date:  1996-03-27       Impact factor: 3.575

7.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.

Authors:  R L Rocha; S G Hilsenbeck; J G Jackson; C L VanDenBerg; C n Weng; A V Lee; D Yee
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

8.  A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.

Authors:  Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

9.  Lipoprotein lipase is frequently overexpressed or translocated in cervical squamous cell carcinoma and promotes invasiveness through the non-catalytic C terminus.

Authors:  S A Carter; N A Foster; C G Scarpini; A Chattopadhyay; M R Pett; I Roberts; N Coleman
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

10.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

View more
  12 in total

1.  m6A mRNA methylation regulates the ERK/NF-κB/AKT signaling pathway through the PAPPA/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer.

Authors:  Peng Ruan; Shujun Wang; Chaoyi Yang; Xiaohui Huang; Pengxing Sun; Aili Tan
Journal:  Cell Biol Toxicol       Date:  2022-08-15       Impact factor: 6.819

2.  The association of obesity with type I uterine cancer-is this an oversimplification?

Authors:  Cortney M Eakin; Cheng-I Liao; Ritu Salani; Joshua G Cohen; Daniel S Kapp; John K Chan
Journal:  Am J Obstet Gynecol       Date:  2022-05-11       Impact factor: 10.693

3.  Prognostic and Clinicopathological Significance of Hypoxia-Inducible Factor-1α in Endometrial Cancer: A Meta-Analysis.

Authors:  Ping Zhu; Longxia Shen; Qiuxia Ren; Qingxiang Zeng; Xiaocui He
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244

Review 4.  New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Authors:  A Talhouk; J N McAlpine
Journal:  Gynecol Oncol Res Pract       Date:  2016-12-13

5.  The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers.

Authors:  Ajit Venniyoor
Journal:  Chin J Cancer       Date:  2017-01-31

6.  Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI.

Authors:  Weijing Wang; Wenjie Jiang; Lin Hou; Haiping Duan; Yili Wu; Chunsheng Xu; Qihua Tan; Shuxia Li; Dongfeng Zhang
Journal:  BMC Genomics       Date:  2017-11-13       Impact factor: 3.969

7.  Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.

Authors:  Joseph F Peevey; Brandon-Luke L Seagle; Kruti P Maniar; J Julie Kim
Journal:  Oncotarget       Date:  2017-06-27

8.  Analysis of the circular RNA transcriptome in endometrial cancer.

Authors:  Bei Jun Chen; Frances L Byrne; Konii Takenaka; Susan C Modesitt; Ellen M Olzomer; James D Mills; Rhonda Farrell; Kyle L Hoehn; Michael Janitz
Journal:  Oncotarget       Date:  2017-12-20

9.  Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.

Authors:  Anne Kolehmainen; Annukka Pasanen; Taru Tuomi; Riitta Koivisto-Korander; Ralf Bützow; Mikko Loukovaara
Journal:  PLoS One       Date:  2020-11-24       Impact factor: 3.240

Review 10.  The Role of Hyperglycemia in Endometrial Cancer Pathogenesis.

Authors:  Frances L Byrne; Amy R Martin; Melidya Kosasih; Beth T Caruana; Rhonda Farrell
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.